Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

  • The 12 Biotechs of Christmas: Six

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

  • The 12 Biotechs of Christmas: Five

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

  • The 12 Biotechs of Christmas: Four

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

  • The Twelve Biotechs of Christmas: Two

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

  • Such A Pleasant Stay

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

  • Sea of Tranquility

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]

  • Tropic of Palatin

    [Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his thoughts and opinions are his own. His previous columns and recent comments can be found on his Stock Gumshoe page.] “He had never seen her body so abandoned, so unconscious […]

  • Ten Common Biotech Investing Mistakes

    [Ed. Note: Dr. KSS writes about medicine biotech stocks for the Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page for his past articles and most recent comments.] Assessing biotechnology stocks involves use of lots of mental microscopes and magnifying lenses. But the task […]

  • Quickster: T2 Biosystems ($TTOO)

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page to see his biography, latest comments and past articles.] About 18 months ago, I came across tiny Boston-area diagnostics start-up […]

  • The State of Things: Ruction at Regulus

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]

  • Conflict Diamonds

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]

  • Recent Author Comments

    On The Rest of the 12 Biotechs of Christmas
    Well, I would say that after all our looking into things, this may be the point on which I have to back down. I wanted non-association with it so no one could ever accuse me of misusing contributions, but I think that same objective could be accomplished b[...]
    On The Rest of the 12 Biotechs of Christmas
    Wow, OK. I pulled up the E-trade site before I posted the number $250M. As of close today, that site has Aurinia's MC as $249.9M. It may be incorrect, but I was not yanking a number from the air. E-Trade and Yahoo give disparate OS numbers. I find that bot[...]
    On The Rest of the 12 Biotechs of Christmas
    Thanks Peter. It's beena busy interval. At night I am hard at work on a chapter for an Australian medical textbook. I am moving back into a nearly 50 year old home that I've owned for 20 years. Soon after I bought it, my career took me out of state. It has[...]
    On The Rest of the 12 Biotechs of Christmas
    Hi Peter: Yes, I feel that is accurate. The present market cap, not counting what things give back with today's ill-informed selling, is $250M, give or take. Given the broad applicability of voclosporin and anticipated global annual sales (they will partne[...]
    On The Rest of the 12 Biotechs of Christmas
    Sorry, I wasn't aware of those.[...]
    On The Rest of the 12 Biotechs of Christmas
    I am trying to remember what we concluded about PayPal? Linling? Glenn?[...]
    On The Rest of the 12 Biotechs of Christmas
    The basic issue is this. We live in an age of terrorism. Terrorism has to be funded. In order to thwart this, banks have radically changed regulations pertaining to bank accounts, their structure, who can open and hold them, who can access them, who can pu[...]
    On The Rest of the 12 Biotechs of Christmas
    You've missed two catalyst-driven upward spurts in share price on $AUPH, but my personal emotion-free opinion is that it has another 1000 percent up to go from where it is today. Getting it approved for a single indication means prescribers may then prescr[...]
    On The Rest of the 12 Biotechs of Christmas
    Arguments of this sort are highly specious....trying to take basic science info about CNI effects on kidneys and presuming that translates into clinically significant behavior is the province of a fool. His conclusions are wildly idiotic, as T-cell mediate[...]
    On The Rest of the 12 Biotechs of Christmas
    New renal biopsies? Utterly ridiculous, dangerous, unjustifiable and medically inappropriate. You'd never get that by an IRB! Only an idiot would make such an assertion...and a non-medical unqualified idiot at that. Great buying opportunity here. A gift[...]
    On The Rest of the 12 Biotechs of Christmas
    You don't think of him as a great contrarian indicator? He doesn't matter in biotech any more.[...]
    On The Rest of the 12 Biotechs of Christmas
    In my view that's exactly the problem. People don't understand it, or as is often the case in biotech are either rogue believers or doubters and won't listen to the expertise of experts. I feel that temporal overhang.....that the story may take til 2020 to[...]
    On The Rest of the 12 Biotechs of Christmas
    Well, as a substitute in what sense? For what reason? The reasons for being on fish oil mostly aren't there, at least not in terms of what people once took them believing them to accomplish.[...]
    On The Rest of the 12 Biotechs of Christmas
    Promising. Glad they've allowed an investigator-initiated trial. Shows mgmt has confidence and that likelihood of clinical uptake by practitioners is high. Sometime I need to do an essay on the upside and downside of investigator-initiated trials, but in t[...]
    On The Rest of the 12 Biotechs of Christmas
    Ja....which raises a good clinical point. When you've got somebody immunosuppressed and they're running a fever, sometimes the most prudent course of action can be to hold the immunosuppression until you're sure it's not behind an emerging septic or viral [...]
    On The Rest of the 12 Biotechs of Christmas
    Trading notice Added to $CRBP pre-market. Position enlarged by 50 percent. Anticipation of positive data in CF using resunab as anti-inflammatory agent[...]
    On The Rest of the 12 Biotechs of Christmas
    Are you now chris28? Regardless, happy birthday to our Antipodean one and good on you for being at that conference.[...]
    On The Rest of the 12 Biotechs of Christmas
    Unfortunately, none I know of. These conferences love the admit fees, and most are far far higher. They generally go to pay rental on the site. Not fair really. The system isn't equitable.[...]
    On The Rest of the 12 Biotechs of Christmas
    Probably from things like anemia and thrombotic events, both of which are common in lupus. $AUPH[...]
    On The Rest of the 12 Biotechs of Christmas
    Kenny: It's possible I've erred in unveiling BSTG too early. The 12 Biotechs were mostly ripe, right-now things, and this one could or can wait til 3Q. I sincerely think they are onto something that will reward shareholders greatly, that they have overcome[...]

    This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.